Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to Constance et al.

Leukemia volume 31, pages 772–773 (2017)Cite this article

Subjects

We thank Drs Constance, Ross and colleagues for their comments on our recommendations.

In the limited space of this response we cannot indulge ourselves in literally quoting our paper, but some comments could be of interest for our Canadian correspondents, and the readers of Leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.

    Article  CAS  Google Scholar 

  2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–386.

    Article  CAS  Google Scholar 

  3. Wilterdink JL, Easton JD . Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992; 49 (8): 857–863.

    Article  CAS  Google Scholar 

  4. Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS et al. Canadian Cardiovascular Society Guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 2016; 32: 831–841.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Hematologia y Grupo 44 IIS-IP, Hospital Universitario de la Princesa, Madrid, Spain

    J L Steegmann

  2. Department of Hematology and Oncology ‘L. and A. Seràgnoli’, St Orsola University Hospital, Bologna, Italy

    M Baccarani

  3. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK

    R E Clark

Authors
  1. J L Steegmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Baccarani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R E Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J L Steegmann.

Ethics declarations

Competing interests

The authors declare the following relationships with pharmaceutical companies: Ariad—receipt of honoraria (JLS, MB) and research funding (JLS); Bristol-Myers-Squibb—receipt of honoraria (JLS, MB, REC), research funding (JLS, REC); Novartis—receipt of honoraria (JLS, MB, REC), research funding (JLS, REC); Pfizer—receipt of honoraria (JLS, MB, REC) and research funding (JLS, REC); Sanofi—receipt of honoraria (REC) and research funding (REC).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steegmann, J., Baccarani, M. & Clark, R. Reply to Constance et al.. Leukemia 31, 772–773 (2017). https://doi.org/10.1038/leu.2016.337

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.337

Search

Advanced search

Quick links